Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.22
(-9.76%)
SEK 2.22
(-9.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -43.05 Million SEK | -9.85% |
| 2022 | -37.22 Million SEK | -46.6% |
| 2021 | -26.27 Million SEK | -12.65% |
| 2020 | -22.68 Million SEK | 0.15% |
| 2019 | -22.72 Million SEK | -46.74% |
| 2018 | -15.48 Million SEK | -95.89% |
| 2017 | - SEK | -3.03% |
| 2016 | 88.00 SEK | -1272.54% |
| 2015 | 16.00 SEK | -1652.78% |
| 2014 | 263.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.5 Million SEK | 20.73% |
| 2024 Q1 | -9.17 Million SEK | 31.93% |
| 2023 Q1 | -8.86 Million SEK | 24.79% |
| 2023 Q3 | -11.58 Million SEK | -69.81% |
| 2023 Q2 | -6.82 Million SEK | 23.01% |
| 2023 FY | - SEK | -9.85% |
| 2023 Q4 | -10.36 Million SEK | 10.55% |
| 2022 Q3 | -6.18 Million SEK | 35.11% |
| 2022 Q4 | -11.78 Million SEK | -90.53% |
| 2022 FY | - SEK | -46.6% |
| 2022 Q1 | -9.97 Million SEK | -50.54% |
| 2022 Q2 | -9.53 Million SEK | 4.47% |
| 2021 Q3 | -8 Million SEK | -54.18% |
| 2021 FY | - SEK | -12.65% |
| 2021 Q4 | -6.62 Million SEK | 17.16% |
| 2021 Q1 | -5.73 Million SEK | 51.82% |
| 2021 Q2 | -5.19 Million SEK | 9.46% |
| 2020 FY | - SEK | 0.15% |
| 2020 Q2 | -1.73 Million SEK | 60.33% |
| 2020 Q1 | -4.37 Million SEK | 37.63% |
| 2020 Q3 | -4.68 Million SEK | -170.24% |
| 2020 Q4 | -11.89 Million SEK | -153.86% |
| 2019 Q3 | -7.44 Million SEK | -89.75% |
| 2019 Q4 | -7 Million SEK | 5.82% |
| 2019 FY | - SEK | -46.74% |
| 2019 Q1 | -4.34 Million SEK | 28.22% |
| 2019 Q2 | -3.92 Million SEK | 9.71% |
| 2018 Q2 | -3.1 Million SEK | -4.12% |
| 2018 FY | - SEK | -95.89% |
| 2018 Q4 | -6.05 Million SEK | -80.87% |
| 2018 Q3 | -3.34 Million SEK | -7.76% |
| 2018 Q1 | -2.98 Million SEK | -22.71% |
| 2017 Q3 | -2.11 Million SEK | -16.37% |
| 2017 Q1 | -1.53 Million SEK | 17.52% |
| 2017 Q2 | -1.82 Million SEK | -18.41% |
| 2017 FY | - SEK | -3.03% |
| 2017 Q4 | -2.43 Million SEK | -14.74% |
| 2016 Q1 | -2.69 Million SEK | -466.21% |
| 2016 FY | - SEK | -1272.54% |
| 2016 Q4 | -1.86 Million SEK | -77.81% |
| 2016 Q3 | -1.04 Million SEK | 69.82% |
| 2016 Q2 | -3.47 Million SEK | -28.64% |
| 2015 FY | - SEK | -1652.78% |
| 2015 Q2 | -381 Thousand SEK | 37.95% |
| 2015 Q3 | -302 Thousand SEK | 20.73% |
| 2015 Q4 | 737 Thousand SEK | 344.04% |
| 2015 Q1 | -614 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -214.462% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | -13.692% |
| BioGaia AB (publ) | 466.19 Million SEK | 109.235% |
| Enzymatica AB (publ) | -41.12 Million SEK | -4.696% |
| Gabather AB (publ) | 37 Thousand SEK | 116459.459% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -191.49% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | -59.696% |
| Nanexa AB (publ) | -70.79 Million SEK | 39.183% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -248.89% |
| ODI Pharma AB | 1.36 Million SEK | 3248.615% |
| Orexo AB (publ) | -22 Million SEK | -95.695% |
| Probi AB (publ) | 115.61 Million SEK | 137.239% |
| Swedencare AB (publ) | 484 Million SEK | 108.895% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.595% |
| Toleranzia AB | -7.39 Million SEK | -481.955% |
| Vivesto AB | -89.75 Million SEK | 52.034% |